Dr. Jahanzeb on Challenges in Non-Driver Adenocarcinoma

Mohammad Jahanzeb, MD
Published Online: Wednesday, Nov 30, 2016



Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the challenges researchers must overcome in patients with non-driver adenocarcinoma.

One of the major challenges, Jahanzeb says, is that there are too many clinical trials that are competing with each other. Also, there is still not enough tissue testing, he adds.

Additionally, there needs to be a multidisciplinary approach to treatment.

Universities and institutions may have tumor boards, but there needs to be a tumor board available for every practice, he explains. The issue of clinical trials will not be overcome by any 1 factor, because researchers in the community often work on their own compounds along with their own vested interest.

Consortiums of physicians and cooperative groups can align incentives in a way so that trials are prioritized. It would be helpful to centralize clearing mechanisms in which the superior trials and designs will continue through the pipeline, while poor ones will not, Jahanzeb says.


Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the challenges researchers must overcome in patients with non-driver adenocarcinoma.

One of the major challenges, Jahanzeb says, is that there are too many clinical trials that are competing with each other. Also, there is still not enough tissue testing, he adds.

Additionally, there needs to be a multidisciplinary approach to treatment.

Universities and institutions may have tumor boards, but there needs to be a tumor board available for every practice, he explains. The issue of clinical trials will not be overcome by any 1 factor, because researchers in the community often work on their own compounds along with their own vested interest.

Consortiums of physicians and cooperative groups can align incentives in a way so that trials are prioritized. It would be helpful to centralize clearing mechanisms in which the superior trials and designs will continue through the pipeline, while poor ones will not, Jahanzeb says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations®: Identifying Best Practices of the Multidisciplinary Team in CINV ManagementJun 28, 20172.0
Community Practice Connections™: A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer PatientsJun 29, 20172.0
Publication Bottom Border
Border Publication
$emailPop$